Rosiglitazone
Microsatellite Instability-High Solid Malignant Tumor
Dan ZandbergSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Microsatellite Instability-High Solid Malignant Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Neonc Technologies, Inc. | Phase 2 | B |
Nivolumab Neonc Technologies, Inc. | Phase 2 | B |
Letrozole Dan Zandberg | Phase 2 | CCC |
Metformin Dan Zandberg | Phase 2 | CCC |
Irinotecan Neonc Technologies, Inc. | Phase 1/2 | CC |
View all 14 →
Same molecule, other indications
Rosiglitazone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →